コンテンツへスキップ
Merck

A5844

Sigma-Aldrich

Monoclonal Anti-c-Abl antibody produced in mouse

clone ABL-148, ascites fluid

別名:

Anti-ABL, Anti-BCR-ABL, Anti-CHDSKM, Anti-JTK7, Anti-bcr/abl, Anti-c-ABL, Anti-c-ABL1, Anti-p150, Anti-v-abl

ログイン組織・契約価格を表示する


About This Item

MDL番号:
UNSPSCコード:
12352203
NACRES:
NA.44

由来生物

mouse

品質水準

結合体

unconjugated

抗体製品の状態

ascites fluid

抗体製品タイプ

primary antibodies

クローン

ABL-148, monoclonal

分子量

antigen 145 kDa

化学種の反応性

monkey, rat, human, mouse, bovine

テクニック

flow cytometry: suitable
immunocytochemistry: suitable
immunoprecipitation (IP): suitable
microarray: suitable
western blot: 1:2,000 using human melanoma cell extract

アイソタイプ

IgG2a

UniProtアクセッション番号

輸送温度

dry ice

保管温度

−20°C

ターゲットの翻訳後修飾

unmodified

遺伝子情報

human ... ABL1(25)
mouse ... Abl1(11350)
rat ... Abl1(311860)

詳細

The c-Abl protein contains three high mobility group-like domains that bind to AT-rich DNA in a cooperative manner.
c-Abl is a proto-oncogene product that belongs to Tyr protein kinase family. It has a crucial role in different cellular processes like- differentiation, adhesion and regulates DNA damage-induced apoptosis.

特異性

Mouse anti-c-Abl antibody reacts specifically with an epitope present in the SH2 domain of the c-Abl. The product has also shown reactivity for c-Abl of monkey, rat, bovine, mouse and human.

免疫原

リコンビナントc-AblのSH2ドメイン。

アプリケーション

Monoclonal anti-c-Abl antibody can be used in western blotting (diluted 1:2000) using melanoma cell extract from human. It can also be used in microarray and flow cytometry. Monoclonal anti-c-Abl antibody can be used for studying the mechanism of signaling pathways involving c-Abl. It may also be used for immunoprecipitation and immunocytochemistry.

生物化学的/生理学的作用

Cytoplasmic c-Abl regulates SH2/SH3 adaptor protein cytoskeleton-associated adaptor protein (Crk) and the Crk-binding protein p130cas. Nuclear c-Abl has been implicated in the regulation of cell cycle-dependent and DNA damage-induced gene expression.

ターゲットの説明

c-Abl is a non-receptor tyrosine kinase with both cytoplasmic and nuclear functions. The Abl oncogen has been implicated in several human leukemias including nearly all chronic myelocytic leukemias.

免責事項

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

適切な製品が見つかりませんか。  

製品選択ツール.をお試しください

保管分類コード

10 - Combustible liquids

WGK

nwg

引火点(°F)

Not applicable

引火点(℃)

Not applicable


適用法令

試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。

Jan Code

A5844-.2ML:
A5844-BULK:
A5844-VAR:


試験成績書(COA)

製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。

以前この製品を購入いただいたことがある場合

文書ライブラリで、最近購入した製品の文書を検索できます。

文書ライブラリにアクセスする

c-Abl: activation and nuclear targets
Shaul Y
Cell Death and Differentiation, 7(1), 10-10 (2000)
Cytoplasmic c-Abl provides a molecular `Rheostat?controlling carcinoma cell survival and invasion
Kain KH, et al.
Oncogene, 22(38), 6071-6071 (2003)
Qianyi Bao et al.
Cell communication and signaling : CCS, 22(1), 247-247 (2024-05-01)
Renal fibrosis is a prevalent manifestation of chronic kidney disease (CKD), and effective treatments for this disease are currently lacking. Myofibroblasts, which originate from interstitial fibroblasts, aggregate in the renal interstitium, leading to significant accumulation of extracellular matrix and impairment
Lukasz Skora et al.
European journal of haematology, 96(5), 502-506 (2015-07-15)
Binding of tyrosine kinase inhibitors such as imatinib was shown to induce a novel open-inhibited conformation of BCR-ABL, in which Tyr245 is exposed and prone to phosphorylation. To evaluate whether this leads to priming of the kinase in cellular systems
Lukasz Skora et al.
Proceedings of the National Academy of Sciences of the United States of America, 110(47), E4437-E4445 (2013-11-06)
Successful treatment of chronic myelogenous leukemia is based on inhibitors binding to the ATP site of the deregulated breakpoint cluster region (Bcr)-Abelson tyrosine kinase (Abl) fusion protein. Recently, a new type of allosteric inhibitors targeting the Abl myristoyl pocket was

資料

Quantitative and qualitative western blotting to validate knockdown by esiRNA.

ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.

製品に関するお問い合わせはこちら(テクニカルサービス)